The final quarter of 2023 saw a rally in seemingly everything, which caught most investors off-guard, especially in fixed income markets. The US 10 year Treasury yield had peaked near 5% back in October, before falling to around 3.9% by the end of 2023. Some investors hope that the momentum from the fourth quarter of 2023 will accelerate in the new year. So is the bond market poised to skyrocket in 2024? On Money in the Market, Hongbin Jeong speaks to Omar Slim, Co-Head of Asia ex-Japan of Fixed Income at PineBridge Investments, to find out more about the outlook of fixed income markets in 2024.

The final quarter of 2023 saw a rally in seemingly everything, which caught most investors off-guard, especially in fixed income markets. The US 10 year Treasury yield had peaked near 5% back in October, before falling to around 3.9% by the end of 2023. Some investors hope that the momentum from the fourth quarter of 2023 will accelerate in the new year. So is the bond market poised to skyrocket in 2024? On Money in the Market, Hongbin Jeong speaks to Omar Slim, Co-Head of Asia ex-Japan of Fixed Income at PineBridge Investments, to find out more about the outlook of fixed income markets in 2024.

Take a step back, refocus, and Reset with Lynlee.

Airing weekdays from 1pm to 4pm, the show brings clarity to the stories shaping Singapore and the world — from current affairs and global developments to business trends and industry shifts. Through insightful conversations and fresh perspectives, Lynlee explores what’s driving the headlines and where things are heading next.

Featuring segments like Viewpoint, Industry Insight and Suite Talk, Reset goes beyond the noise to offer thoughtful analysis, real-world context and ideas that help you recalibrate for the rest of your day.

Take a step back, refocus, and Reset with Lynlee.
Airing weekdays from 1pm to 4pm, the show brings clarity to the stories shaping Singapore and the world &mdash; from current affairs and global developments to business trends and industry shifts. Through insightful conversations and fresh perspectives, Lynlee explores what&rsquo;s driving the headlines and where things are heading next.
Featuring segments like Viewpoint, Industry Insight and Suite Talk, Reset goes beyond the noise to offer thoughtful analysis, real-world context and ideas that help you recalibrate for the rest of your day.

Reset with Lynlee

MONEY FM 89.3 is Singapore’s first and only Business and Personal Finance station. MONEY FM is a 24-hour English talk format station featuring local and international business and financial news. We provide you with financial market and currency updates and insights from analysts, economists, policy makers, industry experts and business owners.

In the lighter hours, listen to discussions on social issues and features on topics that include health, education, arts and music.

MONEY FM 89.3 is Singapore&rsquo;s first and only Business and Personal Finance station. MONEY FM is a 24-hour English talk format station featuring local and international business and financial news. We provide you with financial market and currency updates and insights from analysts, economists, policy makers, industry experts and business owners.
In the lighter hours, listen to discussions on social issues and features on topics that include health, education, arts and music.

MONEY FM 89.3 is Singapore’s first and only Business and Personal Finance station.

MONEY FM 89.3

Take a step back, refocus, and Reset with Lynlee.

Reset with Lynlee (1pm – 4pm)

Money in the Market: Are future rate cuts ideal for bond investors?

Biotech innovation is no longer driven solely by large pharmaceutical companies. Increasingly, breakthroughs are coming from startups, universities and specialist firms, but turning promising science into real-world treatments remains a long and uncertain journey.

On Industry Insight, Lynlee Foo speaks with Dr Alan Russell, Vice President of Research Biologics at Amgen, about how the biotech innovation model has evolved, what separates startups that successfully commercialise scientific discoveries from those that fall short, how AI is reshaping the industry, and why Singapore is emerging as a growing hub for biotech innovation.

Biotech innovation is no longer driven solely by large pharmaceutical companies. Increasingly, breakthroughs are coming from startups, universities and specialist firms, but turning promising science into real-world treatments remains a long and uncertain journey.
On Industry Insight, Lynlee Foo speaks with Dr Alan Russell, Vice President of Research Biologics at Amgen, about how the biotech innovation model has evolved, what separates startups that successfully commercialise scientific discoveries from those that fall short, how AI is reshaping the industry, and why Singapore is emerging as a growing hub for biotech innovation.

Industry Insight: What does it take for a biotech to succeed aside from great science?

Businesses have long focused on making supply chains faster, leaner and cheaper. But after years of global disruption, many are now willing to pay more to make sure they can keep operating when the unexpected happens.

Lynlee Foo speaks with Chris Hampden, Senior Vice President at Proxima, the global procurement and supply chain consultancy that is part of Bain & Company, about why supply chain resilience has become a boardroom priority, how companies are balancing cost against risk, whether consumers will eventually pay the price, and why AI is both strengthening and complicating global supply chains.

Businesses have long focused on making supply chains faster, leaner and cheaper. But after years of global disruption, many are now willing to pay more to make sure they can keep operating when the unexpected happens.
Lynlee Foo speaks with Chris Hampden, Senior Vice President at Proxima, the global procurement and supply chain consultancy that is part of Bain &amp; Company, about why supply chain resilience has become a boardroom priority, how companies are balancing cost against risk, whether consumers will eventually pay the price, and why AI is both strengthening and complicating global supply chains.

Industry Insight: How much is supply chain resilience worth?

Singapore wants to build healthcare AI models trained on local patient data, with the aim of improving the early detection and treatment of chronic diseases. But better AI depends on better data. Would you be comfortable letting AI learn from medical data from people like you if it could lead to better healthcare? Lynlee Foo explores the trade-off between medical progress, privacy and trust in today's AI Dilemma.

Singapore wants to build healthcare AI models trained on local patient data, with the aim of improving the early detection and treatment of chronic diseases. But better AI depends on better data. Would you be comfortable letting AI learn from medical data from people like you if it could lead to better healthcare? Lynlee Foo explores the trade-off between medical progress, privacy and trust in today's AI Dilemma.

Money in the Market: Are future rate cuts ideal for bond investors?

In 2 playlist(s)

Reset with Lynlee (1pm – 4pm)

Social links

Follow podcast

Recent clips